Pharming Group to report fourth quarter and full year 2024 financial results on March 13
Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced it will release its preliminary (unaudited) fourth quarter and full year 2024 financial results on Thursday, March 13, 2025. The company will host an analyst and investor presentation at 13:30 CET/08:30 am EDT on the same day.
The presentation will include a conference call for which participants must register in advance to receive dial-in information and a unique PIN. Questions will only be taken from dial-in attendees. A live webcast of the presentation will also be available through advance registration.
Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR) ha annunciato che pubblicherà i suoi risultati finanziari preliminari (non verificati) del quarto trimestre e dell'intero anno 2024 il giovedì 13 marzo 2025. L'azienda ospiterà una presentazione per analisti e investitori alle 13:30 CET/08:30 am EDT nello stesso giorno.
La presentazione includerà una conferenza telefonica per la quale i partecipanti devono registrarsi in anticipo per ricevere le informazioni per la chiamata e un PIN unico. Le domande saranno accettate solo dai partecipanti in chiamata. Sarà inoltre disponibile una diretta streaming della presentazione tramite registrazione anticipata.
Pharming Group (Euronext Ámsterdam: PHARM/Nasdaq: PHAR) ha anunciado que publicará sus resultados financieros preliminares (no auditados) del cuarto trimestre y del año completo 2024 el jueves 13 de marzo de 2025. La compañía llevará a cabo una presentación para analistas e inversores a las 13:30 CET/08:30 am EDT el mismo día.
La presentación incluirá una conferencia telefónica para la cual los participantes deben registrarse con antelación para recibir información de acceso y un PIN único. Las preguntas solo se aceptarán de los asistentes que llamen. También estará disponible una transmisión en vivo de la presentación mediante registro previo.
파밍 그룹 (유로넥스트 암스테르담: PHARM/Nasdaq: PHAR)는 2024년 4분기 및 전체 연도 재무 결과를 2025년 3월 13일 목요일에 발표할 것이라고 발표했습니다. 회사는 같은 날 13:30 CET/08:30 am EDT에 애널리스트 및 투자자 발표를 개최할 예정입니다.
발표에는 참가자가 사전 등록하여 전화 접속 정보와 고유 PIN을 받아야 하는 전화 회의가 포함됩니다. 질문은 전화로 참석한 분들만 받을 수 있습니다. 사전 등록을 통해 발표의 실시간 웹캐스트도 제공됩니다.
Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR) a annoncé qu'elle publiera ses résultats financiers préliminaires (non audités) du quatrième trimestre et de l'année entière 2024 le jeudi 13 mars 2025. L'entreprise organisera une présentation pour les analystes et les investisseurs à 13h30 CET/08h30 EDT le même jour.
La présentation comprendra une conférence téléphonique pour laquelle les participants doivent s'inscrire à l'avance pour recevoir les informations de connexion et un code PIN unique. Les questions ne seront prises qu'en compte des participants par téléphone. Une diffusion en direct de la présentation sera également disponible par le biais d'une inscription préalable.
Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR) hat angekündigt, dass es seine vorläufigen (unauditierten) Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 am Donnerstag, den 13. März 2025 veröffentlichen wird. Das Unternehmen wird am selben Tag um 13:30 CET/08:30 Uhr EDT eine Präsentation für Analysten und Investoren veranstalten.
Die Präsentation wird eine Telefonkonferenz beinhalten, für die sich die Teilnehmer im Voraus registrieren müssen, um Anrufinformationen und eine eindeutige PIN zu erhalten. Fragen werden nur von Anrufern entgegengenommen. Ein Live-Streaming der Präsentation wird ebenfalls nach vorheriger Registrierung verfügbar sein.
- None.
- None.
Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended December 31, on Thursday, March 13, 2025.
Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 13, 2025.
To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.
Conference call registration:
Please note, the Company will only take questions from dial-in attendees.
https://register.vevent.com/register/BI7d716758d12d4ad588b70fdbca665b6a
To watch the live webcast, please register in advance using the link below.
Webcast registration:
https://edge.media-server.com/mmc/p/7qvoovac
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, UK
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Attachment
FAQ
When will Pharming Group (PHARM) release its Q4 and full year 2024 results?
What time is Pharming Group's (PHARM) Q4 2024 earnings call?
How can investors participate in Pharming Group's (PHARM) Q4 2024 earnings call?
Is there a webcast available for Pharming Group's (PHARM) Q4 2024 earnings presentation?
